Table 3.
Treatment exposure and subsequent therapy
| LDAC | LDAC + volasertib | |
|---|---|---|
| No. of patients treated | 45 | 42 |
| No. of cycles, median (range) | ||
| All patients | 2 (1-12) | 2 (1-22) |
| Patients with response | 7 (5-11) | 8 (2-22) |
| Patients without response | 2 (1-12) | 2 (1-10) |
| Days on treatment, median (range) | ||
| All patients | 64 (11-459) | 85 (12-869) |
| Patients with response | 214 (153-350) | 309 (83-869) |
| Patients without response | 56 (11-459) | 59 (12-355) |
| Patients discontinued study treatment, n | 45 | 40 |
| No other antileukemia therapy after discontinuation, n (%) | 17 (38) | 24 (60) |
| New antileukemia therapy after discontinuation, n (%) | 28 (62)* | 16 (40)* |
*
In the LDAC arm, 3 patients received subsequent anthracycline-based therapy; in the LDAC + volasertib arm, 1 patient.